title: [Pandemic influenza in Russia: specific features of clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease].
abstract: OBJECTIVE
  To assess efficacy and safety of ingavirin in the treatment of the flu caused by pandemic virus of flu A (H1N1) sw1 in hospitalized patients compared with oseltamivir.
  
  
  METHODS
  A population-based comparative multicenter trial included 194 patients with verified diagnosis of the flu aged 18-60 years with marked clinical symptoms, body temperature over 38 degrees C and duration of the disease 48 hours maximum. The patients were randomized into 2 groups: group 1 (n=152) received ingavirin (90 mg once a day), group 2 received oseltamivir (n=42) in a dose 150 mg twice a day. Duration of the course was 5 days.
  
  
  RESULTS
  Ingavirin and oseltamivir normalized body temperature within treatment hours 24-36 if therapy was initiated in the first disease hours 27.0 +/- 10.0 and 31.9 +/- 10.4. Mean duration of the fever for ingavirin was 35.1 +/- 14.5 hours, for oseltamivir--26.3 +/- 13.0 hours (p < 0.817). The antiviral medicines significantly reduced duration of intoxication (head ache, weakness), catarrhal symptoms (cough, tracheitis, rhinitis), rate of complication vs. patients untreated with antivirus drugs (n=30).
  
  
  CONCLUSIONS
  The results of the treatment show safety and efficacy of ingavirin in uncomplicated flu caused by pandemic virus of flu A (H1N1) sw1 in inpatients. Early etiotropic therapy is a basic treatment policy able to reduce the number of severe complications and lethality.
authors.forename: L V
authors.initials: LV
authors.lastname: Kolobukhina
authors.forename: L N
authors.initials: LN
authors.lastname: Merkulova
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Shchelkanov
authors.forename: E I
authors.initials: EI
authors.lastname: Burtseva
authors.forename: V V
authors.initials: VV
authors.lastname: Lavrishcheva
authors.forename: E I
authors.initials: EI
authors.lastname: Samokhvalov
authors.forename: S V
authors.initials: SV
authors.lastname: Al'khovskiĭ
authors.forename: A G
authors.initials: AG
authors.lastname: Prilipov
authors.forename: E S
authors.initials: ES
authors.lastname: Proshina
authors.forename: S N
authors.initials: SN
authors.lastname: Avdeev
authors.forename: O A
authors.initials: OA
authors.lastname: Sutochnikova
authors.forename: M V
authors.initials: MV
authors.lastname: Bazarova
authors.forename: E I
authors.initials: EI
authors.lastname: Kelli
authors.forename: N D
authors.initials: ND
authors.lastname: Tserukalova
authors.forename: I A
authors.initials: IA
authors.lastname: Blank
authors.forename: O M
authors.initials: OM
authors.lastname: Shestakova
authors.forename: O N
authors.initials: ON
authors.lastname: Kolivashko
authors.forename: T V
authors.initials: TV
authors.lastname: Arseneva
authors.forename: O E
authors.initials: OE
authors.lastname: Ambrosi
authors.forename: A A
authors.initials: AA
authors.lastname: Shul'diakov
authors.forename: A F
authors.initials: AF
authors.lastname: Popov
authors.forename: A I
authors.initials: AI
authors.lastname: Simakova
authors.forename: N A
authors.initials: NA
authors.lastname: Malyshev
authors.forename: A G
authors.initials: AG
authors.lastname: Chuchalin
authors.forename: D K
authors.initials: DK
authors.lastname: L'vov
mesh_terms: D000293:Adolescent; D000328:Adult; D000577:Amides / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002208:Caproates; D003998:Dicarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification*; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000008:administration & dosage / Q000627:therapeutic use*; D058873:Pandemics; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000577:Amides; D000998:Antiviral Agents; D002208:Caproates; D003998:Dicarboxylic Acids; D007093:Imidazoles; D053139:Oseltamivir; C539419:pentanedioic acid imidazolyl ethanamide